Efficient enucleation of erythroblasts differentiated in vitro from hematopoietic stem and progenitor cells.

Cell Engineering Division, RIKEN BioResource Center, Koyadai 3-1-1, Tsukuba, Ibaraki 305-0074, Japan.
Nature Biotechnology (Impact Factor: 39.08). 11/2006; 24(10):1255-6. DOI: 10.1038/nbt1245
Source: PubMed

ABSTRACT Erythroblast enucleation is thought to be largely dependent on signals mediated by other cells, such as macrophages. In an attempt to improve the in vitro production of red blood cells (RBCs) from immature hematopoietic progenitor cells, we have developed a method to produce enucleated RBCs efficiently in the absence of feeder cells. Our method may represent an efficient way to produce transfusable RBCs on a large scale from hematopoietic progenitors.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Epigenetic memory in induced pluripotent stem cells, with regards to their somatic cell type of origin, might lead to variations in their differentiation capacities. In this context, induced pluripotent stem cells from human CD34+ hematopoietic stem cells might be more suitable for hematopoietic differentiation than commonly used fibroblast-derived induced pluripotent stem cells. To investigate the influence of an epigenetic memory on the ex vivo expansion of induced pluripotent stem cells into erythroid cells, we compared induced pluripotent stem cells from human neural stem cells and human cord blood-derived CD34+ hematopoietic stem cells and evaluated their potential for differentiation into hematopoietic progenitor and mature red blood cells. Although genome-wide DNA methylation profiling at all promoter regions demonstrates an epigenetic memory of induced pluripotent stem cells with regards to their somatic cell type of origin, we found a similar hematopoietic induction potential and erythroid differentiation pattern. All human induced pluripotent stem cell lines showed terminal maturation into normoblasts and enucleated reticulocytes, producing predominantly fetal hemoglobin. Differences were only observed in the growth rate of erythroid cells, which was slightly higher in the CD34+ hematopoietic stem cell-derived induced pluripotent stem cells. More detailed methylation analysis of the hematopoietic and erythrocyte promoters identified similar CpG methylation levels in the CD34+-derived and neural stem cell-derived induced pluripotent stem cell lines, which confirms their comparable erythroid differentiation potential.
    Haematologica 10/2014; DOI:10.3324/haematol.2014.108068 · 5.87 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Blood transfusions are routinely done in every medical regimen and a worldwide established collection, processing/storage centers provide their services for the same. There have been extreme global demands for both raising the current collections and supply of safe/adequate blood due to increasingly demanding population. With, various risks remain associated with the donor derived blood, and a number of post collection blood screening and processing methods put extreme constraints on supply system especially in the underdeveloped countries. A logistic approach to manufacture erythrocytes ex-vivo by using modern tissue culture techniques have surfaced in the past few years. There are several reports showing the possibilities of RBCs (and even platelets/neutrophils) expansion under tightly regulated conditions. In fact, ex vivo synthesis of the few units of clinical grade RBCs from a single dose of starting material such as umbilical cord blood (CB) has been well established. Similarly, many different sources are also being explored for the same purpose, such as embryonic stem cells, induced pluripotent stem cells. However, the major concerns remain elusive before the manufacture and clinical use of different blood components may be used to successfully replace the present system of donor derived blood transfusion. The most important factor shall include the large scale of RBCs production from each donated unit within a limited time period and cost of their production, both of these issues need to be handled carefully since many of the recipients among developing countries are unable to pay even for the freely available donor derived blood. Anyways, keeping these issues in mind, present article shall be focused on the possibilities of blood production and their use in the near future.
    Frontiers in Cell and Developmental Biology 06/2014; 2. DOI:10.3389/fcell.2014.00026
  • [Show abstract] [Hide abstract]
    ABSTRACT: Increase and aging of the world population in the next decades will lead to the magnification of the incidence of pathologies requiring transfusion support, and in parallel to a decrease of the proportion of potential donors. This imposes to partly rethink the current model of blood supply for the mid-term. In this context, difficulties to collect blood supplies will become chronic. We will therefore need to dispose of complementary sources of red blood cells (RBC) for transfusion. It is a public health question. The cell therapy approach which consists of generating cultured RBC (cRBC) in vitro after amplification of stem cells (SC) therefore makes sense. To date, the most accessible source of stem cells is cord blood, but still relies on donations. Induced pluripotent adult stem cells (iPS) are the ideal source. These cell lines present the advantage to allow a continuous production and can be chosen according to a phenotype of interest. They may provide treatments to patients in situation of impossible transfusion (alloimmunizated patients, rare phenotypes). Essential progress have allowed to establish the proof of concept of the approach. All steps of upstream research were successfully achieved, including the demonstration of the feasibility of injection into human. This leads us to believe that RBC generated in vitro from stem cells will be the future players of blood transfusion.
    09/2014; DOI:10.1016/j.oncohp.2014.06.001


Available from
May 23, 2014